Dual CD22/CD19 CAR-T Produces Durable Remissions in B-ALL

Company Academic Consortium (Singapore) Event Type Peer-Reviewed Clinical Data Modality Dual-Antigen CAR-T Cell Therapy Asset CART2219.1 (LTG2737) Target CD22 / CD19 Disease Area B-Cell Acute Lymphoblastic Leukemia Summary A peer reviewed Blood Cancer Discovery study reported that all 11 adults and children with relapsed or…